Curis, Inc. (NASDAQ:CRIS)
| CAPS Rating |
|
|---|---|
| Open | $4.96 |
| Previous Close | $4.98 |
| Daily Range | $4.70 - $4.97 |
| 52-Week Range | $2.70 - $5.65 |
| Market Cap | $365.12M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,696,725 |
| Average Daily Volume | 0 |
CRIS
VS S&P 500 (SPY)
How do you think CRIS will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CRIS Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CRIS News and Commentary
- Maximum Market: $2.9 Billion, For Now – The Motley Fool
- This Drug Approval Is Good For the Industry – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- UPDATE:FDA Approves Roche's Erivedge For Basal Cell Skin Cancer – SmartMoney
- US FDA Approves Roche and Curis Skin Cancer Drug – SmartMoney
- In Drug Development, Help Is Crucial – The Motley Fool
- NVAX has the best kind of partner – Blog at The Motley Fool
- Investing 101: Rallying Stocks Under $5 Undervalued to Analyst Estimates – The Motley Fool
- Investing 101: Rallying Stocks Under $5 Undervalued to Analyst Estimates – NASDAQ
- These Cold Stocks Are Heating Up – The Motley Fool
- Data Look Good, Approval Unknown – The Motley Fool
- Bullish Biotech: 5 Biotech Firms Making Great Strides – The Motley Fool
- 5 Biotech ASCO Abstracts to Watch – The Motley Fool
- What This Downgrade Means for You – The Motley Fool
- Curis Shares Popped: What You Need to Know – The Motley Fool
- UPDATE: Roche 'Hedgehog Inhibitor' Shrinks Basal Cancer Tumors -Study – SmartMoney
- Best Performing U.S. Stocks Year to Date – SeekingAlpha
- Let's See Some Data, Curis – The Motley Fool
- UPDATE: Roche's Skin Cancer Drug Meets Mid-Stage Trial Goals – SmartMoney
- Roche's Oral Skin Cancer Drug Meets Mid-Stage Trial Goals – SmartMoney
RSS Headlines
Fool UK
